Richard Cathomas
Richard Cathomas
Onkologie/Hämatologie Kantonsspital Graubünden
Bestätigte E-Mail-Adresse bei ksgr.ch - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage …
ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ...
The Lancet 387 (10024), 1163-1177, 2016
11392016
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer
J Beyer, P Albers, R Altena, J Aparicio, C Bokemeyer, J Busch, ...
Annals of oncology 24 (4), 878-888, 2013
2492013
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
M Pless, R Stupp, HB Ris, RA Stahel, W Weder, S Thierstein, MA Gerard, ...
The Lancet 386 (9998), 1049-1056, 2015
1852015
Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: first survival results from STAMPEDE
N James, M Mason
J Clin Oncol 33 (33), 5001, 2015
1622015
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international …
RA Stahel, O Riesterer, A Xyrafas, I Opitz, M Beyeler, A Ochsenbein, ...
The lancet oncology 16 (16), 1651-1658, 2015
1342015
STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive …
ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ...
Lancet 387 (10024), 1163-77, 2016
1252016
Active surveillance is the preferred approach to clinical stage I testicular cancer
CR Nichols, B Roth, P Albers, LH Einhorn, R Foster, S Daneshmand, ...
Journal of Clinical Oncology 31 (28), 3490-3493, 2013
1172013
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)
AJ Templeton, V Dutoit, R Cathomas, C Rothermundt, D Bärtschi, ...
European urology 64 (1), 150-158, 2013
1092013
Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl‐2 and Bcl‐xL antisense treatment
S Hopkins‐Donaldson, R Cathomas, AP Simões‐Wüst, S Kurtz, ...
International journal of cancer 106 (2), 160-166, 2003
1042003
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib …
GA Pesce, D Klingbiel, K Ribi, A Zouhair, R Von Moos, M Schlaeppi, ...
European journal of cancer 48 (3), 377-384, 2012
912012
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up
F Honecker, J Aparicio, D Berney, J Beyer, C Bokemeyer, R Cathomas, ...
Annals of oncology 29 (8), 1658-1686, 2018
902018
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09)
C Rothermundt, S Hayoz, AJ Templeton, R Winterhalder, RT Strebel, ...
European urology 66 (3), 468-474, 2014
842014
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
G Del Conte, C Sessa, R Von Moos, L Vigano, T Digena, A Locatelli, ...
British journal of cancer 111 (4), 651-659, 2014
772014
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)
R Von Moos, B Seifert, M Simcock, SM Goldinger, S Gillessen, ...
Annals of oncology 23 (2), 531-536, 2012
732012
Serum levels of microRNA-371a-3p (M371 test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study
KP Dieckmann, A Radtke, L Geczi, C Matthies, P Anheuser, U Eckardt, ...
Journal of Clinical Oncology 37 (16), 1412, 2019
592019
The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a …
F Strasser, D Blum, R Von Moos, R Cathomas, K Ribi, S Aebi, D Betticher, ...
Annals of Oncology 27 (2), 324-332, 2016
592016
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV …
M Sebastian, A Papachristofilou, C Weiss, M Früh, R Cathomas, W Hilbe, ...
BMC cancer 14 (1), 748, 2014
582014
Sensitivity comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase II imaging study
GP Nicolas, N Schreiter, F Kaul, J Uiters, H Bouterfa, J Kaufmann, ...
Journal of Nuclear Medicine 59 (6), 915-921, 2018
492018
First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase …
A Ravaud, S Oudard, G Gravis-Mescam, E Sevin, S Zanetta, C Theodore, ...
J Clin Oncol 27 (Suppl), 5146, 2009
492009
A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma
F Stenner, R Chastonay, H Liewen, SR Haile, R Cathomas, ...
Oncology 82 (6), 333-340, 2012
452012
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20